O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma

Oncogene

Volumn 28, Issue 9, 2009, Pages 1280-1284

  Bachmaier, R ^a   Aryee, D N T ^a   Jug, G ^a   Kauer, M ^a   Kreppel, M ^a   Lee, K A ^b   Kovar, H ^a,c  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Ewing's sarcoma; EWS FLI1; O GlcNAc; Phosphorylation; Post translational modification; Transcription

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLGLUCOSAMINYLATION; GLUCOSAMINE DERIVATIVE; HEXOSAMINE; HYBRID PROTEIN; INHIBITOR OF DIFFERENTIATION 2; PHOSPHOPROTEIN; SERINE; THREONINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; EWING SARCOMA; EWS FLI1 GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLYCOSYLATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACYLATION; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; TRANSCRIPTION, GENETIC;

EID: 62049084331     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.484     Document Type: Article

References (24)

1. Araya N, Hiraga H, Kako K, Arao Y, Kato S, Fukamizu A. (2005). Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1. Biochem Biophys Res Commun 329: 653-660.
2. Aryee DN, Kreppel M, Bachmaier R, Uren A, Muehlbacher K, Wagner S et al (2006). Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Res 66: 9862-9869.
3. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
4. Deloulme JC, Prichard L, Delattre O, Storm DR. (1997). The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain (in process citation). J Biol Chem 272: 27369-27377.
5. Guinamard R, Fougereau M, Seckinger P. (1997). The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS. Scand J Immunol 45: 587-595.
6. Gupta R, Brunak S. (2002). Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput, 310-322.
7. Hart GW, Housley MP, Slawson C. (2007). Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446: 1017-1022.
8. Kelly WG, Dahmus ME, Hart GW. (1993). RNA polymerase II is a glycoprotein. Modification of the COOH-terminal domain by O-GlcNAc. J Biol Chem 268: 10416-10424.
9. Kim J, Lee JM, Branton PE, Pelletier J. (1999). Modification of EWS/WT1 functional properties by phosphorylation. Proc Natl Acad Sci USA 96: 14300-14305.
10. Kim J, Lee JM, Branton PE, Pelletier J. (2000). Modulation of EWS/WT1 activity by the v-Src protein tyrosine kinase. FEBS Lett 474: 121-128.
11. Kovar H. (2005). Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 15: 189-196.
12. Lynch G, Kemeny N, Casper E. (1982). Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am J Clin Oncol 5: 541-543.
13. Martin K, Steinberg TH, Cooley LA, Gee KR, Beechem JM, Patton WF. (2003). Quantitative analysis of protein phosphorylation status and protein kinase activity on microarrays using a novel fluorescent phosphorylation sensor dye. Proteomics 3: 1244-1255.
14. Matsuoka Y, Matsuoka Y, Shibata S, Yasuhara N, Yoneda Y. (2002). Identification of Ewing's sarcoma gene product as a glycoprotein using a monoclonal antibody that recognizes an immunodeterminant containing O-linked N-acetylglucosamine moiety. Hybrid Hybridomics 21: 233-236.
15. Ng KP, Potikyan G, Savene RO, Denny CT, Uversky VN, Lee KA. (2007). Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc Natl Acad Sci USA 104: 479-484.
16. Ohlson J, Enstero M, Sjoberg BM, Ohman M. (2005). A method to find tissue-specific novel sites of selective adenosine deamination. Nucleic Acids Res 33: e167.
17. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. (1998). Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II (In Process Citation). Oncogene 17: 603-610.
18. Rahman A, Smith FP, Luc PT, Woolley PV. (1985). Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Invest New Drugs 3: 369-374.
19. Snow CM, Senior A, Gerace L. (1987). Monoclonal antibodies identify a group of nuclear pore complex glycoproteins. J Cell Biol 104: 1143-1156.
20. Spahn L, Siligan C, Bachmaier R, Schmid JA, Aryee DN, Kovar H. (2003). Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. Oncogene 22: 6819-6829.
21. Sullivan MP, Nelson JA, Feldman S, Van Nguyen B. (1988). Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharmacol 21: 78-84.
22. Wang M, Xie Y, Girnita L, Nilsson G, Dricu A, Wejde J et al. (1999). Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Exp Cell Res 246: 38-46.
23. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW. (2002). Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics 1: 791-804.
24. Zhang XK, Watson DK. (2005). The FLI-1 transcription factor is a short-lived phosphoprotein in T cells. J Biochem (Tokyo) 137: 297-302.